1 Comment
User's avatar
User's avatar
Comment removed
Nov 3
Comment removed
Andrii Buvailo, PhD's avatar

Yes, and I think the case for big tech companies' involvement in the core R&D processes will only be growing. Because pharma/biotech's big data strategies and AI pilots are increasingly tied to infrastructure, computation, and digital resources that are hard/impossible to build internally.